Should Grade Group 1 (GG1) be called cancer?
Introduction ISUP Grade Group 1 prostate cancer is the lowest histologic grade of prostate cancer with a clinically indolent course. Removal of the term ‘cancer’ has been proposed and has historical precedent both in urothelial and thyroid carcinoma. Methods Evidence-based review identifying argumen...
Gespeichert in:
| Veröffentlicht in: | World journal of urology 2022, Vol.40 (1), p.15-19 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 19 |
|---|---|
| container_issue | 1 |
| container_start_page | 15 |
| container_title | World journal of urology |
| container_volume | 40 |
| creator | Labbate, Craig V. Paner, Gladell P. Eggener, Scott E. |
| description | Introduction
ISUP Grade Group 1 prostate cancer is the lowest histologic grade of prostate cancer with a clinically indolent course. Removal of the term ‘cancer’ has been proposed and has historical precedent both in urothelial and thyroid carcinoma.
Methods
Evidence-based review identifying arguments for and against Grade Group 1 being referred to as cancer.
Results
Grade Group 1 has histologic evidence of tissue microinvasion and 0.3–3% rate of extraprostatic extension. Genomic evaluation suggests overlap of a minority of Grade Group 1 cancers with those of Grade Group 2. Conversely, Grade Group 1 tumors appear to have distinct genetic and genomic profiles from Grade Group 3 or higher tumors. Grade Group 1 has no documented ability for regional or distant metastasis and long-term follow up after treatment or active surveillance is safe with excellent oncologic outcomes.
Discussion
Grade Group 1 prostate cancer, while showing evidence of neoplasia on histology has a remarkably indolent natural history more akin to non-neoplastic precursor lesions. Consideration should be given to renaming Grade Group 1 prostate cancer, which has the potential to minimize overtreatment, treatment-related side effects, patient anxiety, and financial burden on the healthcare system. |
| doi_str_mv | 10.1007/s00345-020-03583-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2477263354</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2477263354</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-7030f964d0b97373f237baa15293f7f7b8fae0e32b17b643c8fb864869f28d643</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotn78AQ-y4KWC0Ukmm2RPIkVXoeBBPYf9SLRlu1uT7sF_b-pWBQ9eMpA8807mIeSEwSUDUFcBAEVKgQMFTDVSsUPGTCBSrbjcJWNQXFCRaRyRgxAWAExJSPfJCFEgT0GOycXTW9c3dZL7orbx7PpVwpJJnrPzpLRJVTSNrWNpK-uvj8ieK5pgj7f1kLzc3T5P7-nsMX-Y3sxohSpdUwUILpOihjJTqNBxVGVRsJRn6JRTpXaFBYu8ZKqUAivtSi2Flpnjuo4Xh2Qy5K58997bsDbLeahs0xSt7fpguFBxQcR0g579QRdd79v4O8MlTxnnCFmk-EBVvgvBW2dWfr4s_IdhYDYuzeDSRJfmy6XZRJ9uo_tyaeuflm95EcABCPGpfbX-d_Y_sZ_xbnnE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2625122309</pqid></control><display><type>article</type><title>Should Grade Group 1 (GG1) be called cancer?</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Labbate, Craig V. ; Paner, Gladell P. ; Eggener, Scott E.</creator><creatorcontrib>Labbate, Craig V. ; Paner, Gladell P. ; Eggener, Scott E.</creatorcontrib><description>Introduction
ISUP Grade Group 1 prostate cancer is the lowest histologic grade of prostate cancer with a clinically indolent course. Removal of the term ‘cancer’ has been proposed and has historical precedent both in urothelial and thyroid carcinoma.
Methods
Evidence-based review identifying arguments for and against Grade Group 1 being referred to as cancer.
Results
Grade Group 1 has histologic evidence of tissue microinvasion and 0.3–3% rate of extraprostatic extension. Genomic evaluation suggests overlap of a minority of Grade Group 1 cancers with those of Grade Group 2. Conversely, Grade Group 1 tumors appear to have distinct genetic and genomic profiles from Grade Group 3 or higher tumors. Grade Group 1 has no documented ability for regional or distant metastasis and long-term follow up after treatment or active surveillance is safe with excellent oncologic outcomes.
Discussion
Grade Group 1 prostate cancer, while showing evidence of neoplasia on histology has a remarkably indolent natural history more akin to non-neoplastic precursor lesions. Consideration should be given to renaming Grade Group 1 prostate cancer, which has the potential to minimize overtreatment, treatment-related side effects, patient anxiety, and financial burden on the healthcare system.</description><identifier>ISSN: 0724-4983</identifier><identifier>EISSN: 1433-8726</identifier><identifier>DOI: 10.1007/s00345-020-03583-4</identifier><identifier>PMID: 33432506</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Genomics ; Humans ; Male ; Medicine ; Medicine & Public Health ; Metastases ; Neoplasm Grading ; Nephrology ; Oncology ; Prostate cancer ; Prostatic Neoplasms - classification ; Prostatic Neoplasms - pathology ; Terminology as Topic ; Thyroid carcinoma ; Topic Paper ; Tumors ; Urology</subject><ispartof>World journal of urology, 2022, Vol.40 (1), p.15-19</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-7030f964d0b97373f237baa15293f7f7b8fae0e32b17b643c8fb864869f28d643</citedby><cites>FETCH-LOGICAL-c375t-7030f964d0b97373f237baa15293f7f7b8fae0e32b17b643c8fb864869f28d643</cites><orcidid>0000-0001-5839-6640 ; 0000-0002-5748-3790 ; 0000-0001-6749-4701</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00345-020-03583-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00345-020-03583-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33432506$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Labbate, Craig V.</creatorcontrib><creatorcontrib>Paner, Gladell P.</creatorcontrib><creatorcontrib>Eggener, Scott E.</creatorcontrib><title>Should Grade Group 1 (GG1) be called cancer?</title><title>World journal of urology</title><addtitle>World J Urol</addtitle><addtitle>World J Urol</addtitle><description>Introduction
ISUP Grade Group 1 prostate cancer is the lowest histologic grade of prostate cancer with a clinically indolent course. Removal of the term ‘cancer’ has been proposed and has historical precedent both in urothelial and thyroid carcinoma.
Methods
Evidence-based review identifying arguments for and against Grade Group 1 being referred to as cancer.
Results
Grade Group 1 has histologic evidence of tissue microinvasion and 0.3–3% rate of extraprostatic extension. Genomic evaluation suggests overlap of a minority of Grade Group 1 cancers with those of Grade Group 2. Conversely, Grade Group 1 tumors appear to have distinct genetic and genomic profiles from Grade Group 3 or higher tumors. Grade Group 1 has no documented ability for regional or distant metastasis and long-term follow up after treatment or active surveillance is safe with excellent oncologic outcomes.
Discussion
Grade Group 1 prostate cancer, while showing evidence of neoplasia on histology has a remarkably indolent natural history more akin to non-neoplastic precursor lesions. Consideration should be given to renaming Grade Group 1 prostate cancer, which has the potential to minimize overtreatment, treatment-related side effects, patient anxiety, and financial burden on the healthcare system.</description><subject>Genomics</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Neoplasm Grading</subject><subject>Nephrology</subject><subject>Oncology</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - classification</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Terminology as Topic</subject><subject>Thyroid carcinoma</subject><subject>Topic Paper</subject><subject>Tumors</subject><subject>Urology</subject><issn>0724-4983</issn><issn>1433-8726</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kE1LAzEQhoMotn78AQ-y4KWC0Ukmm2RPIkVXoeBBPYf9SLRlu1uT7sF_b-pWBQ9eMpA8807mIeSEwSUDUFcBAEVKgQMFTDVSsUPGTCBSrbjcJWNQXFCRaRyRgxAWAExJSPfJCFEgT0GOycXTW9c3dZL7orbx7PpVwpJJnrPzpLRJVTSNrWNpK-uvj8ieK5pgj7f1kLzc3T5P7-nsMX-Y3sxohSpdUwUILpOihjJTqNBxVGVRsJRn6JRTpXaFBYu8ZKqUAivtSi2Flpnjuo4Xh2Qy5K58997bsDbLeahs0xSt7fpguFBxQcR0g579QRdd79v4O8MlTxnnCFmk-EBVvgvBW2dWfr4s_IdhYDYuzeDSRJfmy6XZRJ9uo_tyaeuflm95EcABCPGpfbX-d_Y_sZ_xbnnE</recordid><startdate>2022</startdate><enddate>2022</enddate><creator>Labbate, Craig V.</creator><creator>Paner, Gladell P.</creator><creator>Eggener, Scott E.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5839-6640</orcidid><orcidid>https://orcid.org/0000-0002-5748-3790</orcidid><orcidid>https://orcid.org/0000-0001-6749-4701</orcidid></search><sort><creationdate>2022</creationdate><title>Should Grade Group 1 (GG1) be called cancer?</title><author>Labbate, Craig V. ; Paner, Gladell P. ; Eggener, Scott E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-7030f964d0b97373f237baa15293f7f7b8fae0e32b17b643c8fb864869f28d643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Genomics</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Neoplasm Grading</topic><topic>Nephrology</topic><topic>Oncology</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - classification</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Terminology as Topic</topic><topic>Thyroid carcinoma</topic><topic>Topic Paper</topic><topic>Tumors</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Labbate, Craig V.</creatorcontrib><creatorcontrib>Paner, Gladell P.</creatorcontrib><creatorcontrib>Eggener, Scott E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>World journal of urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Labbate, Craig V.</au><au>Paner, Gladell P.</au><au>Eggener, Scott E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Should Grade Group 1 (GG1) be called cancer?</atitle><jtitle>World journal of urology</jtitle><stitle>World J Urol</stitle><addtitle>World J Urol</addtitle><date>2022</date><risdate>2022</risdate><volume>40</volume><issue>1</issue><spage>15</spage><epage>19</epage><pages>15-19</pages><issn>0724-4983</issn><eissn>1433-8726</eissn><abstract>Introduction
ISUP Grade Group 1 prostate cancer is the lowest histologic grade of prostate cancer with a clinically indolent course. Removal of the term ‘cancer’ has been proposed and has historical precedent both in urothelial and thyroid carcinoma.
Methods
Evidence-based review identifying arguments for and against Grade Group 1 being referred to as cancer.
Results
Grade Group 1 has histologic evidence of tissue microinvasion and 0.3–3% rate of extraprostatic extension. Genomic evaluation suggests overlap of a minority of Grade Group 1 cancers with those of Grade Group 2. Conversely, Grade Group 1 tumors appear to have distinct genetic and genomic profiles from Grade Group 3 or higher tumors. Grade Group 1 has no documented ability for regional or distant metastasis and long-term follow up after treatment or active surveillance is safe with excellent oncologic outcomes.
Discussion
Grade Group 1 prostate cancer, while showing evidence of neoplasia on histology has a remarkably indolent natural history more akin to non-neoplastic precursor lesions. Consideration should be given to renaming Grade Group 1 prostate cancer, which has the potential to minimize overtreatment, treatment-related side effects, patient anxiety, and financial burden on the healthcare system.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>33432506</pmid><doi>10.1007/s00345-020-03583-4</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0001-5839-6640</orcidid><orcidid>https://orcid.org/0000-0002-5748-3790</orcidid><orcidid>https://orcid.org/0000-0001-6749-4701</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0724-4983 |
| ispartof | World journal of urology, 2022, Vol.40 (1), p.15-19 |
| issn | 0724-4983 1433-8726 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2477263354 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Genomics Humans Male Medicine Medicine & Public Health Metastases Neoplasm Grading Nephrology Oncology Prostate cancer Prostatic Neoplasms - classification Prostatic Neoplasms - pathology Terminology as Topic Thyroid carcinoma Topic Paper Tumors Urology |
| title | Should Grade Group 1 (GG1) be called cancer? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T19%3A59%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Should%20Grade%20Group%201%20(GG1)%20be%20called%20cancer?&rft.jtitle=World%20journal%20of%20urology&rft.au=Labbate,%20Craig%20V.&rft.date=2022&rft.volume=40&rft.issue=1&rft.spage=15&rft.epage=19&rft.pages=15-19&rft.issn=0724-4983&rft.eissn=1433-8726&rft_id=info:doi/10.1007/s00345-020-03583-4&rft_dat=%3Cproquest_cross%3E2477263354%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2625122309&rft_id=info:pmid/33432506&rfr_iscdi=true |